# Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

> **NCT05270200** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT05270200
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270200, "Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05270200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*